Resmed Inc. Stock
Price
Target price
€214.90
€214.90
-0.420%
-0.9
-0.420%
€259.74
12.12.25 / Tradegate
WKN: 895878 / Symbol: RMD / Name: ResMed / Stock / Healthcare Equipment & Supplies / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Resmed Inc. Stock
The price for the Resmed Inc. stock decreased slightly today. Compared to yesterday there is a change of -€0.900 (-0.420%).
With 22 Buy predictions and not a single Sell prediction Resmed Inc. is an absolute favorite of our community.
With a target price of 259 € there is a positive potential of 20.52% for Resmed Inc. compared to the current price of 214.9 €.
Pros and Cons of Resmed Inc. in the next few years
Pros
?
S********** s********
?
M***** P*******
?
C******** o* t** e**********
Cons
?
B****
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Resmed Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Resmed Inc. | -0.420% | -2.451% | -1.557% | -7.251% | -3.329% | 2.480% | 27.160% |
| Veeva Systems A | -2.530% | -8.494% | -25.810% | -14.424% | -6.422% | 16.328% | -12.755% |
| Thermo Fisher Scientific Inc. | -1.250% | -0.885% | -3.923% | -2.812% | -2.393% | -9.506% | 25.280% |
| Waters Corp. | -2.270% | -1.851% | -0.090% | -8.541% | -6.046% | 4.504% | 67.889% |
Comments
ResMed (NYSE:RMD) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Show more
Ratings data for RMD provided by MarketBeat
ResMed (NYSE:RMD) had its price target raised by analysts at Royal Bank Of Canada from $300.00 to $303.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for RMD provided by MarketBeat
ResMed (NYSE:RMD) had its price target raised by analysts at KeyCorp from $298.00 to $299.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RMD provided by MarketBeat
News
Could GLP-1 Drugs Make ResMed's CPAP Machines Obsolete?
ResMed (NYSE: RMD) finds itself in an investment limbo as revolutionary weight loss drugs create both immediate opportunities and long-term existential questions for the sleep apnea device maker.
